Replimune Group, Inc. (REPL)

CIK 0001737953 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2026 8-K (2026-06-29) · 99.1
Latest Q3-2026 8-K (2026-02-03) · 99.1
Q2-2026 8-K (2025-11-06) · 99.1
Q1-2026 8-K (2025-08-07) · 99.1
FY-2025 8-K (2025-05-22) · 99.1
Q3-2025 8-K (2025-02-12) · 99.1
Q2-2025 8-K (2024-11-12) · 99.1
Q1-2025 8-K (2024-08-08) · 99.1
FY-2024 8-K (2024-05-16) · 99.1
Q3-2024 8-K (2024-02-08) · 99.1
Q2-2024 8-K (2023-11-07) · 99.1
Q1-2024 8-K (2023-08-03) · 99.1 · 99.2

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Audit Information
—
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Comprehensive Loss (P)
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Cash Flows
Notes
Accrued Expenses and Other Current Liabilities
Benefit Plans
—
Collaboration and Other Arrangements
—
Commitments and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Debt
—
Fair Value of Financial Assets and Liabilities
Geographic Information
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Long-term Debt
—
Nature of The Business
Net Loss Per Share
Pay Vs Performance Disclosure
Pre-funded Warrants
Property, Plant and Equipment, Net
Segment Information
Short-term Investments
Significant Agreements
Stock-based Compensation
Stockholders' Equity
Subsequent Events
Summary of Significant Accounting Policies